MGC Diagnostics Corporation Reports 2014 Second Quarter Operating Results - Tucson News Now

MGC Diagnostics Corporation Reports 2014 Second Quarter Operating Results

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE MGC Diagnostics Corporation

SAINT PAUL, Minn., June 12, 2014 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today reported financial results for the second quarter ended April 30, 2014.

Second Quarter Fiscal 2014 Highlights:

  • Net Income for the 2014 second quarter increased 22% to $308,000, or $0.07 per diluted share, compared to net income of $252,000, or $0.06 per diluted share in the 2013 second quarter;
  • Second quarter revenue was $7.4 million, compared to $7.6 in the 2013 second quarter;
  • Sequential quarterly revenue grew 17.8% versus the fiscal 2014 first quarter,;
  • International sales for the quarter increased 27% to $1.6 million, compared to last year's period;
  • Second quarter service revenue increased 35% on a year-over-year basis;
  • The second quarter Attachment Rate of point-of-sale extended service contracts improved to 32%, compared to 27% in the 2013 second quarter;
  • Second quarter 2014 recurring revenue (service and supplies revenues) totaled $3.2 million, or 43% of total revenue;
  • The Company achieved 12 second quarter competitive account conversions, resulting in $839,000 of revenue;
  • Second quarter current and long-term deferred revenue was $5.9 million;
  • Backlog at the end of the second quarter was $542,000, an increase of 46% from the first quarter of fiscal 2014;
  • Strong balance sheet with $11.4 million in cash and cash equivalents, $15.4 million of working capital and no long-term debt; and
  • At October 31, 2013, the Company had federal net operating loss carry forwards of approximately $12.8 million that may be used to offset a portion of the Company's future tax liability.

Todd M. Austin, Chief Executive Officer of MGC Diagnostics, said, "Our fiscal 2014 second quarter results demonstrate significant improvement compared to our fiscal 2014 first quarter. We continue to have orders in our pipeline that have been delayed due to customer uncertainties regarding the financial impact of the Affordable Care Act, which has lengthened our sales cycle.  Management anticipates MGC will close these orders during fiscal 2014 as the industry more fully understands the reimbursement issues under the Affordable Care Act."

Second quarter fiscal 2014 revenue of $7.4 million was comparable to $7.6 million in the second quarter of fiscal 2013. Domestic 2014 second quarter sales decreased 7% to $5.9 million compared to $6.3 million in the second quarter of 2013, while international sales increased 27% to $1.6 million from $1.2 million for last year's second quarter. Second quarter Group Purchasing Organization ("GPO") sales increased 5% to $4.1 million, compared to $3.9 million in the prior year's second quarter.

Equipment, supplies and accessories sales decreased 9% in the 2014 second quarter to $5.8 million compared to $6.4 million in the 2013 second quarter. Service revenues increased 35% to $1.6 million in the 2014 second quarter, compared to $1.2 million in the 2013 second quarter. The Attachment Rate, which tracks the sale of extended service contracts at the point of new equipment sales, increased to 32% for the fiscal 2014 second quarter, compared to 27% for the same period last year.

Gross margin increased slightly to 55.8%, compared to 55.7% for the 2013 second quarter, primarily due to revenue mix as our service revenue comprised a greater percentage of revenue in the 2014 second quarter.  Gross margin for equipment, supplies and accessories decreased slightly to 52.8% for the second fiscal quarter of 2014, compared to 52.9% for the prior year's quarter. Gross margin for services decreased to 66.4% for the quarter, compared to 70.3% for the prior year's quarter, due primarily to the higher costs associated with servicing extended service contracts.

Second quarter 2014 general and administrative expenses totaled $1.3 million, or 17.3% of revenue, compared to $1.2, or 16.0% of revenue in the comparable quarter last year. Sales and marketing expenses were $1.9 million, or 25.4% of revenue, compared to $2.1 million, or 27.7% of revenue, in the 2013 second quarter. Research and development expenses were $640,000, or 8.6% of revenue, compared to $640,000, or 8.5% of revenue in last year's second quarter. 

Second quarter operating income improved to $327,000, compared to operating income of $258,000 in the 2013 second quarter. For the 2014 second quarter, the Company reported net income of $308,000, or $0.07 per diluted share, compared to net income of $252,000, or $0.06 per diluted share, in the 2013 second quarter.

"We enter the second half of fiscal 2014 with a robust sales pipeline, a solid balance sheet with cash in excess of $11 million and no long-term debt," continued Mr. Austin. "We are well positioned to leverage our newly formed strategic partnership with Sleep Virtual, as we enter the adjacent Cardiorespiratory diagnostic market for the detection, classification and management of sleep apnea. This, and other strategic opportunities, allows us to strengthen our competitive and financial position."

Mark W. Sheffert, Chairman of the Board of Directors, said, "The recently appointed executive management team of CEO Todd Austin, President Matt Margolies and COO and CFO Wes Winnekins, is dedicated to leveraging the progress achieved by our employees and business partners over the past two years to drive operational and financial results with the goal of rewarding our loyal shareholders. We look forward to the opportunities ahead with great anticipation."

Net Operating Loss Carry Forward
At October 31, 2013, the Company had federal net operating loss carry forwards of approximately $12.8 million, not subject to IRC annual limitations on use.  These loss carry forwards will expire in years 2018 through 2032.

Conference Call
The Company has scheduled a conference call for Thursday, June 12, 2014 at 4:30 p.m. ET to discuss its financial results for the second quarter of fiscal year 2014.

Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or listen via a live Internet webcast on the Company's website at www.mgcdiagnostics.com. A replay of the conference call will be available by dialing (877) 344-7529 or (412) 317-0088, confirmation code10047466, through June 19, 2014. A webcast replay of the conference call will be accessible on the Company's website at www.mgcdiagnostics.com for 90 days.

About MGC Diagnostics
MGC Diagnostics Corporation (NASDAQ: MGCD), is a global medical technology company dedicated to cardiorespiratory health solutions. The Company, through its subsidiary Medical Graphics Corporation, develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.  

Cautionary Statement Regarding Forward Looking Statements
From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward-looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in federal securities laws.  These forward-looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward-looking statements. For a list of these factors¸ see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2013, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.

Contact:     


Wesley W. Winnekins    


Joe Dorame, Robert Blum, Joe Diaz



MGC Diagnostics Corporation      


Lytham Partners, LLC



Chief Financial Officer and


(602) 889-9700



Chief Operating Officer


mgcd@lythampartners.com



(651) 484-4874



(Financial Tables to Follow)

 


MGC DIAGNOSTICS CORPORATION AND SUBSIDIARY

Consolidated Balance Sheets

April 30, 2014 and October 31, 2013

(In thousands, except share and per share data)






April 30,


October 31,


2014


2013

Assets

(Unaudited)



Current Assets:






Cash and cash equivalents

$

11,352


$

10,574

Accounts receivable, net of allowance for doubtful accounts of $229 and $147, respectively


6,204



8,048

Inventories, net of obsolescence reserve of $394 and $306, respectively


4,134



3,499

Prepaid expenses and other current assets


1,282



1,102

Total current assets


22,972



23,223

Property and equipment, net of accumulated






depreciation of $4,247 and $4,094, respectively


911



779

Intangible assets, net


2,477



2,189

Total Assets

$

26,360


$

26,191

Liabilities and Shareholders' Equity






Current Liabilities:






Accounts payable

$

2,307


$

1,871

Employee compensation


1,203



1,945

Deferred revenue


3,332



3,091

Other current liabilities and accrued expenses


687



905

Total current liabilities


7,529



7,812

Long-term liabilities:






Long-term deferred revenue and other


2,753



2,535

Total Liabilities


10,282



10,347

Commitments and Contingencies






Shareholders' Equity:






Common stock, $0.10 par value, authorized 25,000,000 shares, 4,223,813 and 4,193,990 shares issued and 4,177,203 and 4,127,896 shares outstanding in 2014 and 2013, respectively


418



413

Undesignated shares, authorized 5,000,000 shares, no shares issued and outstanding


-



-

Additional paid-in capital


22,766



22,606

Accumulated deficit


(7,106)



(7,175)

Total Shareholders' Equity


16,078



15,844

Total Liabilities and Shareholders' Equity

$

26,360


$

26,191







 


MGC DIAGNOSTICS CORPORATION AND SUBSIDIARY

Consolidated Statements of Income (Loss)

(Unaudited in thousands, except per share data)














Three Months ended


Six Months ended


April 30,


April 30,


2014


2013


2014


2013

Revenues












Equipment, supplies and accessories revenues

$

5,798


$

6,360


$

10,757


$

12,166

Service revenues


1,629



1,203



2,974



2,405



7,427



7,563



13,731



14,571

Cost of revenues












Cost of equipment, supplies and accessories revenues


2,736



2,996



5,036



5,831

Cost of service revenues


547



357



987



708



3,283



3,353



6,023



6,539

Gross margin


4,144



4,210



7,708



8,032

Operating expenses:












Selling and marketing


1,884



2,094



3,900



4,220

General and administrative


1,287



1,214



2,430



2,632

Research and development


640



640



1,264



1,287

Amortization of intangibles


6



4



13



11



3,817



3,952



7,607



8,150

Operating income (loss)


327



258



101



(118)

Interest income


-



1



-



1

Income (loss) before taxes


327



259



101



(117)

Provision for taxes


19



7



36



14

Net income (loss)

$

308


$

252


$

65


$

(131)













Income (loss) per share:












Basic

$

0.07


$

0.06


$

0.02


$

(0.03)

Diluted

$

0.07


$

0.06


$

0.02


$

(0.03)

Weighted average common shares outstanding:












Basic


4,163



3,930



4,149



3,910

Diluted


4,237



3,994



4,234



3,910

Dividends declared per share

$

-


$

0.45


$

-


$

0.45













 

MGC DIAGNOSTICS CORPORATION AND SUBSIDIARY

Consolidated Statements of Cash Flows

(Unaudited in thousands)








Six Months ended April 30,


2014


2013

Cash flows from operating activities:






Net income (loss)

$

65


$

(131)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:






          Depreciation


155



110

          Amortization


69



53

          Stock-based compensation


211



234

          Increase(decrease) in allowance for doubtful accounts


82



(13)

          Increase in inventory obsolescence reserve


88



9

          Gain on disposal of equipment


-



(3)

          Changes in operating assets and liabilities:






Accounts receivable


1,762



(625)

Inventories


(723)



(215)

Prepaid expenses and other current assets


(180)



76

Accounts payable


436



(226)

Employee compensation


(742)



42

Deferred revenue


416



1,058

Other current liabilities and accrued expenses


(231)



142

Net cash provided by operating activities


1,408



511







Cash flows from investing activities:






Purchases of property and equipment and intangible assets


(611)



(598)

Net cash used in investing activities


(611)



(598)







Cash flows from financing activities:






Dividends paid


-



(1,800)

Proceeds from issuance of common stock under employee stock purchase plan


67



68

Proceeds from the exercise of stock options


-



345

Repurchase of common stock upon vesting of restricted stock awards


(86)



(23)

Net cash used in financing activities


(19)



(1,410)







Net increase (decrease) in cash and cash equivalents


778



(1,497)

Cash and cash equivalents at beginning of period


10,574



9,665

Cash and cash equivalents at end of period

$

11,352


$

8,168







Cash paid for taxes

$

56


$

18

Supplemental non-cash items:






Current and non-current liabilities issued for leasehold improvements

$

33


$

210

Accrued dividends (reversal)


(4)



56







 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow